| Primary information |
|---|
| sequence ID | Seq_2937 |
| Peptide sequence | GNTEGLQKSLAELGGHLDQQVEEFR |
| CancerPDF_ID | CancerPDF_ID82, CancerPDF_ID349, CancerPDF_ID1080, CancerPDF_ID1387, CancerPDF_ID2631, CancerPDF_ID8582, CancerPDF_ID9570, |
| PMID | 16896061,19795908,16395409,21136997,21136997,23667664,21533267 |
| Protein Name | Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV,Aplipoprotein A-IV,Apolipoprotein A-IV |
| UniprotKB Entry Name | APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Plasma,Serum,Serum |
| M/Z | 2755.2,919.12,2755.2,2754.35729,2754.3573,2754.36,689.6 |
| Charge | 1,3,1,1,1,1,4 |
| Mass (in Da) | 2755.35,NA,NA,NA,NA,2756.99,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,NA,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,NA,0.001,NA,1.49 |
| CancerPDF_ID | CancerPDF_ID82, CancerPDF_ID349, CancerPDF_ID1080, CancerPDF_ID1387, CancerPDF_ID2631, CancerPDF_ID8582, CancerPDF_ID9570, |
| p-Value | 1.00E-05,NA,3.06E-07,8.37E-06,8.37E-06,NA,8.52E-08 |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT |
| Length | 25,25,25,25,25,25,25 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,Swissprot Database (57.4) |
| Modification | NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"40 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",30 patients and 30 healthy controls,27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.11, 12.37 and 1.22 in prostate, bladder and breast cancer respectively",Differentially expressed between cancer vs normal,Differentially expressed between cancer vs normal,NA,Differentially expressed between Lung cancer vs control |
| Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates |
| Sensitivity | 95% on independent dataset,NA,97.5% on independent validation dataset,0.898,0.898,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,0.946,0.946,NA,NA |
| Accuracy | NA,NA,97.5 % on validation dataset,NA,0.917,NA,0.795 |
| Peptide Atlas | PeptideAtlas |
| IEDB | |